Improvement in Health Care Utilization and Pulmonary Function with Fluticasone Propionate in Patients with Steroid-Dependent Asthma at a National Asthma Referral Center

The impact of switching from other inhaled corticosteroids to fluticasone propionate was studied in patients with severe oral-steroid-dependent asthma over a 1-year period. In this open-label prospective study, patients on maintenance doses of oral and inhaled steroids were referred to a national asthma treatment center and were switched from their previous inhaled corticosteroid to fluticasone propionate 880 μg BID. Compared with data collected from the year prior to enrollment, treatment with fluticasone propionate resulted in significant improvements in pulmonary function, oral steroid requirements, and health resource utilization. In addition, five patients were completely weaned off oral steroids.

[1]  W. Busse,et al.  Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. , 1999, The Journal of allergy and clinical immunology.

[2]  S. Holgate,et al.  SUBEPITHELIAL FIBROSIS IN THE BRONCHI OF ASTHMATICS , 1989, The Lancet.

[3]  R. Dockhorn,et al.  Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. , 1994, The Journal of allergy and clinical immunology.

[4]  F. Hampel,et al.  Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. , 1996, Clinical therapeutics.

[5]  Margaret Martin,et al.  The Bureau of Labor Statistics. , 1970 .

[6]  R. Mason.  Time out for asthma. , 1989, Annals of allergy.

[7]  D. Malone,et al.  A national estimate of the economic costs of asthma. , 1997, American journal of respiratory and critical care medicine.

[8]  A. Weinstein,et al.  Outcome of short-term hospitalization for children with severe asthma. , 1992, The Journal of allergy and clinical immunology.

[9]  M. Abramson,et al.  Do dairy products induce bronchoconstriction in adults with asthma? , 1998, The Journal of allergy and clinical immunology.

[10]  T. Haahtela,et al.  Damage of the airway epithelium and bronchial reactivity in patients with asthma. , 1985, The American review of respiratory disease.

[11]  W. Busse,et al.  Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. , 1995, American journal of respiratory and critical care medicine.

[12]  M. Crane.  Charge what you will ... reimbursements are shrinking. , 1998, Medical economics.

[13]  I. Bernstein,et al.  A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. , 1996, The Journal of allergy and clinical immunology.

[14]  P. Gergen,et al.  An economic evaluation of asthma in the United States. , 1992, The New England journal of medicine.

[15]  H. Nelson,et al.  A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. , 1993, The American review of respiratory disease.

[16]  N. Barnes,et al.  Trial of cyclosporin in corticosteroid-dependent chronic severe asthma , 1992, The Lancet.

[17]  L. Ackerson,et al.  Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind, placebo-controlled study. , 1991, Annals of internal medicine.

[18]  J. Anderson,et al.  A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema , 1969, Thorax.

[19]  M. Johnson,et al.  Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. , 1996, The Journal of allergy and clinical immunology.

[20]  N. Hearst,et al.  Costs of visits to emergency departments. , 1996, The New England journal of medicine.